Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2017

01.06.2017 | Review Article

Tranexamic Acid in the Treatment of Melasma: A Review of the Literature

verfasst von: Marina Perper, Ariel Eva Eber, Rachel Fayne, Sebastian Hugo Verne, Robert James Magno, Jessica Cervantes, Mana ALharbi, Ibrahim ALOmair, Abdulkarem Alfuraih, Keyvan Nouri

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Melasma is a common acquired pigmentary disorder marked by irregular hyperpigmented macules or patches and most commonly occurs in women of darker skin color. It is a chronic often-relapsing condition that causes negative psychosocial effects in those affected. Current treatments such as hydroquinone, kojic acid, and retinoids, among others, demonstrate variable efficacy and side-effect profiles. We conducted a comprehensive literature review examining the use of tranexamic acid (TA), a well-known anti-fibrinolytic agent, in the treatment of melasma. TA delivered orally, topically, and through physical methods works via the inhibition of ultraviolet (UV)-induced plasmin activity in keratinocytes. Predefined search terms were entered into PubMed. Articles were then independently screened by two authors to include only those written in the English language and relating to human subjects with at least mild melasma. The search identified 28 articles, 15 of which met the criteria for full review. The review revealed that TA treatment for melasma is equally effective or more effective than other standard therapies and may induce fewer side effects. Our comprehensive review suggests that TA may be a promising treatment option for melasma because of its demonstrated effectiveness alone and in combination with other modalities as well as its limited side-effect profile.
Literatur
1.
Zurück zum Zitat Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol. 2009;84(6):623–35.CrossRefPubMed Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol. 2009;84(6):623–35.CrossRefPubMed
2.
Zurück zum Zitat Chang M. Melasma. In: Bolognia J, editor. Dermatology. 3rd ed. Amsterdam: Elsevier; 2012. Chang M. Melasma. In: Bolognia J, editor. Dermatology. 3rd ed. Amsterdam: Elsevier; 2012.
11.
15.
Zurück zum Zitat Li Y, Sun Q, He Z, Fu L, He C, Yan Y. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial. J Eur Acad Dermatol Venereol. 2014;28(3):393–4. doi:10.1111/jdv.12209.CrossRefPubMed Li Y, Sun Q, He Z, Fu L, He C, Yan Y. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial. J Eur Acad Dermatol Venereol. 2014;28(3):393–4. doi:10.​1111/​jdv.​12209.CrossRefPubMed
16.
Zurück zum Zitat Tan AW, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. [Epub 13 May 2016]. doi:10.1111/ajd.12474. Tan AW, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. [Epub 13 May 2016]. doi:10.​1111/​ajd.​12474.
19.
Zurück zum Zitat Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435–42. doi:10.1111/dsu.12060.CrossRefPubMed Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435–42. doi:10.​1111/​dsu.​12060.CrossRefPubMed
20.
Zurück zum Zitat Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):520. doi:10.4103/0019-5154.164416.PubMedPubMedCentral Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):520. doi:10.​4103/​0019-5154.​164416.PubMedPubMedCentral
21.
Zurück zum Zitat Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10(40):40–3. Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10(40):40–3.
23.
Zurück zum Zitat Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5 % tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012;14(3):150–4. doi:10.3109/14764172.2012.685478.CrossRefPubMed Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5 % tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012;14(3):150–4. doi:10.​3109/​14764172.​2012.​685478.CrossRefPubMed
24.
Zurück zum Zitat Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174–7. doi:10.1111/jocd.12152.CrossRefPubMed Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174–7. doi:10.​1111/​jocd.​12152.CrossRefPubMed
25.
Zurück zum Zitat Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753–7.PubMedPubMedCentral Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753–7.PubMedPubMedCentral
26.
Zurück zum Zitat Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626–31. doi:10.1111/j.1524-4725.2006.32133.x.PubMed Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626–31. doi:10.​1111/​j.​1524-4725.​2006.​32133.​x.PubMed
27.
Zurück zum Zitat Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139–43. doi:10.4103/0974-2077.118403.CrossRefPubMedPubMedCentral Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139–43. doi:10.​4103/​0974-2077.​118403.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78–83. doi:10.1016/j.jaad.2009.10.051 (e1–2).CrossRefPubMed Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78–83. doi:10.​1016/​j.​jaad.​2009.​10.​051 (e1–2).CrossRefPubMed
33.
Zurück zum Zitat Lee DH, Oh IY, Koo KT, Suk JM, Jung SW, Park JO, et al. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Skin Res Technol. 2014;20(2):208–12. doi:10.1111/srt.12107.CrossRefPubMed Lee DH, Oh IY, Koo KT, Suk JM, Jung SW, Park JO, et al. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Skin Res Technol. 2014;20(2):208–12. doi:10.​1111/​srt.​12107.CrossRefPubMed
35.
Zurück zum Zitat Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med. 1999;106(6):650–4.CrossRefPubMed Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med. 1999;106(6):650–4.CrossRefPubMed
36.
Zurück zum Zitat Byun SY, Chae JB, Na JI, Park KC. Significant improvement in crow’s feet after treatment with Jet-M and a mixed solution of copper–GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and beta-glucan (GHR formulation). J Cosmet Laser Ther. 2016;18(5):293–5. doi:10.3109/14764172.2016.1157367.CrossRefPubMed Byun SY, Chae JB, Na JI, Park KC. Significant improvement in crow’s feet after treatment with Jet-M and a mixed solution of copper–GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and beta-glucan (GHR formulation). J Cosmet Laser Ther. 2016;18(5):293–5. doi:10.​3109/​14764172.​2016.​1157367.CrossRefPubMed
Metadaten
Titel
Tranexamic Acid in the Treatment of Melasma: A Review of the Literature
verfasst von
Marina Perper
Ariel Eva Eber
Rachel Fayne
Sebastian Hugo Verne
Robert James Magno
Jessica Cervantes
Mana ALharbi
Ibrahim ALOmair
Abdulkarem Alfuraih
Keyvan Nouri
Publikationsdatum
01.06.2017
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0263-3

Weitere Artikel der Ausgabe 3/2017

American Journal of Clinical Dermatology 3/2017 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.